Trials / Recruiting
RecruitingNCT04240366
Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- Sponsor
- University of Luebeck · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Additional left atrial appendage isolation during balloon ablation for persistent or long-standing persistent atrial fibrillation can reduce atrial fibrillation reoccurrence within 3-12 months compared to balloon-based pulmonary vein isolation only.
Detailed description
The intervention in the LALA-LAND-AF trial is the additional LAAI in patients with catheter ablation for persistent AF and will be performed once as index ablation as outlined above. With exception of the index ablation, all patients will be treated according to the current clinical practice guidelines for AF as stated by the European Society of Cardiology (ESC) 11,18 and an expert consensus statement on catheter and surgical ablation1. Patients may be treated with a specific antiarrhythmic drug (AAD) for a maximum of 3 months following the index ablation. No repeat ablation for AF should be performed within the first 3 months. Thereafter, repeat ablations are permitted for recurrent AF irrespective of group allocation. Ablation strategy at repeat ablation includes PV re-isolation if required in both groups and re-isolation of the LAA in the intervention group. In the control group, LAAI may only be performed in case all PV were isolated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Control intervention | patients treated with balloon-based ablation of AF by PVI |
| PROCEDURE | Experimental intervention | patients treated with balloon-based ablation of AF by PVI |
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2028-06-01
- Completion
- 2028-08-01
- First posted
- 2020-01-27
- Last updated
- 2024-08-29
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04240366. Inclusion in this directory is not an endorsement.